In Locally Recurrent Breast Cancer (LRBC) and in Malignant Melanoma hyperthermia in combination with radiotherapy is included in leading guidelines:


Breast Cancer

Germany

Harms W, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Krug D, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Wenz F, Sauer R:
DEGRO practical guidelines for radiotherapy of breast cancer VI: therapy of locoregional breast cancer recurrences.
Strahlenther Onkol April 2016, Vol. 192, Issue 4, pp 199–208
OPEN ACCESS https://link.springer.com/article/10.1007/s00066-015-0939-7

AGO (Arbeitsgemeinschaft Gynäkologische Onkologie innerhalb der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft e.V. (DKG)
Guidelines Breast, Version 2023.1E, Loco-Regional Recurrence,
OPEN ACCESS AGO_2023E_17_Loco-Regional_Recurrence.pdf (ago-online.de)
Page 12, 13, 14

Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e.V. und Deutschen Krebshilfe e.V.
Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms; Langversion 4.4–Juni2021AWMF-Registernummer: 032-045OL
OPEN ACCESS https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Mammakarzinom_4_0/Version_4.4/LL_Mammakarzinom_Langversion_4.4.pdf

Netherlands

Richtlijn Borstkanker, Netherlands
OPEN ACCESS https://richtlijnendatabase.nl/richtlijn/borstkanker/locoregionaal_recidief/behandeling.html
Chapter 10 "Locoregionaal recidief"

 

 

Malignant Melanoma

Germany

S3-Leitlinie zur Diagnostik,Therapie und Nachsorge des Melanoms
Version 3.3 – Juli 2020 AWMF-Register-Nummer: 032/024OL

Kapitel 6.7 Radiotherapie bei lokoregionalen Metastasen
Kapitel 7.7 Radiotherapie von Fernmetastasen
OPEN ACCESS https://www.awmf.org/uploads/tx_szleitlinien/032-024OLl_S3_Melanom-Diagnostik-Therapie-Nachsorge_2020-08.pdf

 

 

ESHO Guidelines

In 2017, the European Society of Hyperthermic Oncology has issued quality assurance guidelines:

Trefná HD, Crezee H, Schmidt M, Marder D, Lamprecht U, Ehmann M, Hartmann J, Nadobny J, Gellermann J, van Holthe N, Ghadjar P, Lomax N, Abdel-Rahman S, Bert C, Bakker A, Hurwitz MD, Diederich CJ, Stauffer PR, van Rhoon GC
Quality assurance guidelines for superficial hyperthermia clinical trials:
I. Clinical requirements.

Int J Hyperthermia. 2017 Jan 31:1-12
OPEN ACCESS https://www.tandfonline.com/doi/full/10.1080/02656736.2016.1277791

Dobšíček Trefná H, Crezee J, Schmidt M, Marder D, Lamprecht U, Ehmann M, Nadobny J, Hartmann J, Lomax N, Abdel-Rahman S, Curto S, Bakker A, Hurwitz MD, Diederich CJ, Stauffer PR, Van Rhoon GC
Quality assurance guidelines for superficial hyperthermia clinical trials:
II. Technical requirements for heating devices.

Strahlenther Onkol. 2017 May;193(5):351-366.
OPEN ACCESS https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405104/

Water-filtered infrared A is listed as an appropriate and accepted technique. The hydrosun®-TWH1500 device is compliant with these requirements.

 

Print